Evaluating the effect of Ekangaveera Ras and Trayodashanga Guggulu after Karpasasthyadi Taila Nasya in the patients having Avabahuka (Frozen Shoulder Disorder).

Evaluating the efficacy of Ekangaveera Ras over Trayodashanga Guggulu after Karpasasthyadi Taila Nasya in the management of Avabahuka (Frozen Shoulder Disorder)- A Randomised controlled clinical trial - NIL

Status

Active, not recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/10/096471

Enrollment

Registered

2025-10-24

Start date

Unknown

Completion date

Unknown

Last updated

2025-11-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: M00-M99- Diseases of the musculoskeletal system and connective tissue

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: 1.Subjects aged between 31 and 60 years (irrespective of sex,socio-economic status) fulfilling the diagnostic criteria for Avabahuka (ICD 11 TM2 – Frozen Shoulder Disorder (SP15). 2.Subjects with a clinical diagnosis of Primary Frozen Shoulder Disorder/ primary adhesive capsulitis of the shoulder joint. 3.Diabetic individuals with frozen shoulder, provided their blood glucose levels are well-controlled (e.g., specifying HbA1c less than 8.0% or fasting plasma glucose less than 140 mg/dL, and post-prandial plasma glucose less than 250 mg/dL). 4.Patients deemed fit for Nasya Karma. 5.Patients willing to sign the consent form for the clinical study.

Exclusion criteria

Exclusion criteria: 1.Subjects with a history of fracture or dislocation of the shoulder joint. 2.Subjects diagnosed with Secondary Frozen Shoulder Disorder /secondary adhesive capsulitis of the shoulder joint (e.g., due to trauma, surgery, or other identifiable systemic diseases that are the direct cause). 3.Patients with contraindications to Nasya Karma. 4.Subjects suffering from any other systemic disorders (e.g., active malignancy, severe cardiac/renal/hepatic disease) that could interfere with the course of intervention or compromise patient safety. 5.Patients with uncontrolled diabetes mellitus 6.Pregnant women and lactating mothers. 7.Subjects currently enrolled in any other clinical trial or receiving other concurrent treatments for frozen shoulder that could interfere with study outcomes. 8.Patients with known hypersensitivity or allergy to any of the study medications (Karpasasthyadi Taila, Ekangaveera Ras, Trayodashanga Guggulu).

Design outcomes

Primary

Measure	Time frame
1.Improvement in Range of Motion (ROM) of shoulder joint and pain intensity as measured by VAS from Pre-treatment to Post-treatmentTimepoint: Baseline after 28 days	—

Secondary

Measure	Time frame
1.Change in Quality of Life (QoL) scores from baseline to the end of the study period EuroQol-5D questionnaire).Timepoint: basline, after 4 weeks, after 8 weeks	—

Countries

India

Contacts

Public ContactProf Dr Jonah S

All India Institute of Ayurveda

jonahdr@gmail.com9448262298

Outcome results